X-Body Biosciences along with SRU Biosystems, proclaimed a notable collaborative breakthrough, in the field of antibody screening, where an SRU BIND label free protein identification base is used for the testing of antibodies.
They have created and ratified a unique BIND Biosensor plan to be used alongside the SRU BIND Reader, leading to a huge escalation (200 fold) in sensitivity, when compared to the erstwhile or preceding versions of the sensor. It permits quantifying sub-nanomolar affinity processes inside 384 or 1536 micro plate formats which are automated for usage in making QC and Drug discovery processes and diagnoses.
The Vice President, X-Body (Antibody Research) Dr.Yan Chen has stated that, research has been carried out for several years, to source out a label less, high throughput screening base to expedite the drug discovery procedures, and the remodeled BIND system delivers, exceptional sensitivity and throughput for screening antibodies.
This novel platform rapidly screens the completely human antibody libraries that are covered by the SRU BIND Biosensor and it also quickly detects and analyzes therapeutic patients.